---
title: 'Senior Director, Clinical Research-Infectious Disease at Vir Biotechnology'
canonical: 'https://feeny.ai/job/senior-director-clinical-research-infectious-disease-vir-biotechnology-san-fhjn8b4m07p5'
type: 'job'
last_seen: '2026-09-12'
---

# Senior Director, Clinical Research-Infectious Disease at Vir Biotechnology

- **Company:** Vir Biotechnology
- **Location:** San Francisco California, United States
- **Posted:** 2026-05-28
- **Last confirmed live:** 2026-09-12
- **Apply:** https://job-boards.greenhouse.io/virbiotechnologyinc/jobs/4700564005

## Job description

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies.

Vir Biotechnology has exclusive rights to the universal PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

We believe the success of our colleagues drives the success of our mission. We are committed to creating a company where everyone feels supported and encouraged to give their best.

## THE OPPORTUNITY

Vir Biotechnology is looking for a Senior Director, Clinical Research-Infectious Disease to facilitate late‑stage clinical development for our hepatitis delta (HDV) portfolio, with a primary focus on activities supporting the Phase III clinical program and health authority submission activities.

Reporting to the VP, Clinical Research, this senior leader will serve as the key clinical voice in shaping and executing the clinical development strategy You will concentrate on advancing our HDV assets through global Phase III,BLA‑enabling activities and support on relevant commercial activities.

This role is located in our San Francisco headquarters with an expectation of at least 3 days per week in office.

## WHAT YOU'LL DO

- Lead one of our HDV Phase 3 studies for Clinical Development and support the Clinical Development Sub team Lead
- Execute the late‑stage clinical development plan providing oversight of Phase III studies, incl, including medical monitoring and benefit–risk assessment
- Lead BLA‑enabling activities and clinical components of global regulatory submissions (e.g., BLA, NDA, MAA) and Health Authority interactions
- Contribute to the development and execution of a life cycle management strategy, including but not limited to potential post marketing commitments from a clinical development perspective
- Partner with Regulatory Affairs, Biostatistics, Data Management, and Medical Writing to ensure clinical datasets, narratives, and summaries meet FDA, EMA, and ICH standards for regulatory filings
- Contribute to key clinical and regulatory documents, including protocols, IBs, IND submissions and reports, clinical study reports, and development plans
- Partner with Regulatory Affairs, Biostatistics, Clinical Operations, Safety, Translational Medicine, and Commercial to develop and execute integrated development and registration strategies
- Interpret and integrate clinical data across studies and drive preparation of internal decision documents, integrated analyses, and external publications/presentations
- Build and maintain strong relationships with investigators, KOLs, and advisory boards in infectious diseases
- Ensure adherence to GCP, ICH guidelines, and SOPs, and contribute to continuous improvement of clinical development processes

## WHO YOU ARE AND WHAT YOU BRING

- MD, or PharmD/PhD and 8-10+ years of clinical development experience in the biopharmaceutical industry, with infectious disease or hepatology experience.  Other therapeutic areas experience(s) may be considered with strong regulatory submission experience.
- Demonstrated late‑stage/registrational experience, including leadership of or major contribution to Phase III programs, and direct experience supporting at least one BLA (or NDA/MAA) submission in a clinical leadership role required
- Deep familiarity with GCP, ICH guidelines, and global regulatory expectations for registrational trials
- Proven ability to design and interpret complex Phase II/III clinical trials and integrated clinical packages, and to interact effectively with Health Authorities, KOLs, and internal senior leadership.
- Demonstrated experience leading cross‑functional teams

## #LI-AS1

#LI-Onsite

## WHO WE ARE AND WHAT WE OFFER

The expected salary range for this position is $235,500 to $329,500 per year. Actual pay will be determined based on experience, qualifications, geographic location, and other job-related factors.

Vir Biotechnology's compensation and benefits are aligned with the current market and commensurate with the person’s experience and qualifications. All full-time employees receive a package that includes compensation, bonus and equity as well as many other Vir Biotechnology benefits and perks such as health and welfare benefit plans, non-accrual paid time off, company shut down for holidays, commuter benefits, 401K match and lunch each day in the office.

Applicants must currently be authorized to work for any employer in the U.S.  We are unable to sponsor or take over sponsorship of an employment Visa at this time.

All employment decisions at Vir Biotechnology are based on legitimate, non-discriminatory business requirements, job duties and individual qualifications. Employment decisions are made without regard to any legally protected characteristics.

This commitment extends to all management practices and decisions, including recruitment and hiring, compensation, appraisal systems, promotions, training and career development programs.  Vir Biotechnology also strongly commits to providing employees with a work environment free of unlawful conduct or harassment.

Vir Biotechnology Human Resources leads recruitment and employment for Vir Biotechnology. Unsolicited resumes sent to the company from recruiters do not constitute any type of relationship between the recruiter and Vir Biotechnology and do not obligate us to pay fees should we hire from those resumes. We ask that external recruiters and/or agencies not contact or present candidates directly to our hiring manager or employees.

For hires based in the United States, Vir Biotechnology, participates in [E-Verify](https://www.e-verify.gov/sites/default/files/everify/posters/EVerifyParticipationPoster.pdf).

[Candidate Privacy Notice](https://www.vir.bio/candidate-notice/)

## About Vir Biotechnology

## Company Overview
- **One-liner**: Vir Biotechnology is a clinical-stage immunology company focused on engineering powerful antibody-based medicines to treat infectious diseases and cancer.
- **Entity Type**: Public (Ticker: VIR)
- **Headquarters**: San Francisco, California, United States
- **Founded**: 2016
- **Founders**: Not publicly available (the company was formed with founding investments from ARCH Venture Partners, the Bill & Melinda Gates Foundation, and others)

## Core Business
- **Primary Industry**: Biotechnology (Immunology, Infectious Disease, Oncology)
- **Target Customers**: Patients with serious infectious diseases (e.g., chronic hepatitis delta, COVID-19, Ebola) and specific cancers; the company's customers are effectively patients and healthcare systems, with revenue coming from partnerships and product sales.
- **Mission/Purpose**: "Power the immune system to transform lives" by delivering potentially transformative medicines for patients with high unmet medical needs.

## Products & Services
- **Next-Generation Antibody Platform**: A proprietary platform that enables the rapid discovery, optimization, and advancement of antibody candidates for infectious diseases.
- **PRO-XTEN® Protease-Releasable Masking Technology**: A platform (exclusive rights for oncology and infectious disease) used to engineer conditionally activated antibodies that are designed to be safer and more effective in treating cancer. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
- **Pipeline Programs**: The company’s pipeline includes leading programs in chronic hepatitis delta virus (HDV) and strategically expanding into oncology. They have demonstrated their ability to discover and develop antibody-based medicines for COVID-19 and Ebola.

## Market Standing
- **Valuation/Market Cap**: Market cap fluctuates with stock price. As of recent reporting, it is in the range of several billion USD. For the most current figure, refer to financial data providers.
- **Key Metric**: As a public company, key metrics include R&D spending, cash position, and pipeline progress. The company had significant revenue from its COVID-19 antibody partnership (sotrovimab) but is now focused on advancing its pipeline.
- **Notable Investors/Partners**: Founding investors include ARCH Venture Partners and the Bill & Melinda Gates Foundation. Key partners include Alnylam Pharmaceuticals and Sanofi (via the Amunix/PRO-XTEN platform).
- **Growth Signals**: The company is actively expanding its oncology pipeline, appointing an SVP of Oncology and a Vice President of Clinical Research-Oncology. It continues to hire across R&D, regulatory, and business development, signaling a phase of growth and pipeline advancement.

## Competitive Advantages
- **Deep Immunology Expertise**: The company has a world-class team with deep knowledge of immunology and antibody engineering.
- **Dual-Platform Strategy**: Combining a powerful antibody discovery platform with the PRO-XTEN® masking technology gives it a unique ability to create both potent and safer therapies.
- **Proven Track Record**: Successfully developed and brought to market a COVID-19 antibody (sotrovimab) and an Ebola treatment (mAb114) on an accelerated timeline, demonstrating execution capability.
- **Focus on Unmet Needs**: Concentrates on diseases with limited treatment options, such as chronic hepatitis delta and hard-to-treat cancers.

## Strategic Focus
- **Infectious Disease Foundation**: Continuing to advance its core programs in infectious diseases, with a leading program in chronic hepatitis delta.
- **Strategic Oncology Expansion**: Building a robust oncology pipeline using its antibody and PRO-XTEN® platforms, with a focus on indications with high unmet need.
- **Pipeline Acceleration**: Leveraging its platforms to rapidly identify, optimize, and advance candidates from concept to clinic.
- **Building for the Long Term**: The company is strategically building its capabilities and team to become a multi-product, multi-indication biotech.

## Why Work Here
- **Mission-Driven**: Employees are directly contributing to developing transformative medicines for patients with serious diseases.
- **World-Class Team**: Opportunity to work alongside industry-leading scientists, clinicians, and business leaders in the U.S. and Europe.
- **Commitment to Fair Pay**: The company has an "unwavering commitment to fair pay" with a rigorous, proactive approach to compensation based on skills and experience. U.S. salary ranges are shared internally for transparency.
- **Generous Benefits**: Includes health benefits and wellness program, unaccrued time off with structured holidays, on-site paid parking, lunch, and transit spending account (in the U.S.).
- **Workplace Culture**: The company emphasizes "Virtues" over values and a culture of urgency and impact.
- **Locations**: Primarily San Francisco, CA, with some remote options for specific roles (e.g., Regulatory Writer). European offices are also part of the company.

## Sources
1. [vir.bio](https://www.vir.bio/)
2. [vir.bio/careers](https://www.vir.bio/careers/)
3. [job-boards.greenhouse.io/virbiotechnologyinc](http://job-boards.greenhouse.io/virbiotechnologyinc)
4. [vir.bio/about/strategy](https://www.vir.bio/about/strategy/)

## Other roles at Vir Biotechnology

- [Senior Director, Head of Clinical Pharmacology](https://feeny.ai/job/senior-director-head-of-clinical-pharmacology-vir-biotechnology-san-francisco-3qer9j2yqjys) — San Francisco California, United States
- [Executive Assistant (Temporary)](https://feeny.ai/job/executive-assistant-temporary-vir-biotechnology-san-francisco-california-7r7tz26bm485) — San Francisco California, United States
- [Associate Director, Principal Data Engineer](https://feeny.ai/job/associate-director-principal-data-engineer-vir-biotechnology-san-francisco-n2cqm4s4ssjq) — San Francisco California, United States
- [Associate Director, Research Strategic Planning and Operation-Project Management](https://feeny.ai/job/associate-director-research-strategic-planning-and-operation-project-management-edgsh2kh6vve) — San Francisco California, United States
- [Director, HR Business Partner](https://feeny.ai/job/director-hr-business-partner-vir-biotechnology-san-francisco-california-x9kr46zchf99) — San Francisco California, United States
- [Associate Director, Clinical Operations](https://feeny.ai/job/associate-director-clinical-operations-vir-biotechnology-san-francisco-5js245pesmxf) — San Francisco California, United States
- [Director, Competitive Intelligence and Insights-Oncology](https://feeny.ai/job/director-competitive-intelligence-and-insights-oncology-vir-biotechnology-san-k8tedfn0r43x) — San Francisco California, United States
- [Director, Toxicology](https://feeny.ai/job/director-toxicology-vir-biotechnology-san-francisco-california-w6j0ynmcyhgc) — San Francisco California, United States
- [Director, Bioanalytics](https://feeny.ai/job/director-bioanalytics-vir-biotechnology-san-francisco-california-d1m2wx6g1rgd) — San Francisco California, United States
- [Associate Director, Clinical Transactional Counsel](https://feeny.ai/job/associate-director-clinical-transactional-counsel-vir-biotechnology-san-zczwjc2nvjck) — San Francisco California, United States